Masterclass: Evidence on the Use of SGLT2is in HF Across the EF Spectrum

Published: 29 Jun 2022

  • Views:

    Views Icon 886
  • Likes:

    Heart Icon 5
Average (ratings)
No ratings
Your rating

Masterclass host, Dr Harriette Van Spall (McMaster University, CA) invites Dr Scott D Solomon (Brigham & Women's Hospital & Harvard Medical School, US) and Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the latest evidence supporting the use of SGLT2 inhibitors in heart failure across the ejection fraction spectrum. 

Dr Solomon provides a brief overview on the existing data including DAPA-HF, EMPEROR-Reduced and Preserved. Dr Kosiborod shares the insights from the DEFINE-HF & PRESERVED-HF Pooled Analysis. Dr Van Spall asks Dr Solomon about DELIVER and the knowledge gap it fills. 

Recorded remotely from Hamilton, Boston and Kansas City, 2022. 

Editor: Mirjam Boros
Videographer: Tom Green, Dan Brent